Key Takeaways
- • Medical University of South Carolina and Revival Healthcare Capital of Austin, Texas announced a five-year strategic collaboration on April 29, 2026, to evaluate and develop early-stage medical devices and health care technologies with no financial obligations attached.
- • Revival Healthcare Capital, a MedTech-focused investment firm, gains access to MUSC's clinical expertise, research laboratories, and statewide network of clinicians for due diligence, clinical trials, and pre-clinical testing of medical devices without sourcing external evaluators.
- • Revival Healthcare Capital previously announced a $458 million joint investment with Olympus Corp. to co-found Swan Endosurgical, developing a robotic surgery platform for gastrointestinal tumor treatment, demonstrating the firm's active portfolio in advanced medical devices.
- • The partnership was catalyzed by existing local connections, specifically Revival managing partner Rick Anderson's residence in Charleston and his established relationship with MUSC President Dr. David J. Cole, positioning MUSC as Revival's preferred partner for technology evaluation and advancement.
- • The collaboration creates a streamlined framework for medical device development by combining venture capital due diligence capabilities with academic research infrastructure and clinical validation resources.
Summary
The Medical University of South Carolina and Revival Healthcare Capital, a Texas-based MedTech venture investment firm, formalized a five-year strategic partnership announced on April 29, 2026, designed to accelerate the evaluation and development of innovative medical devices and health care technologies. The agreement carries no direct financial obligations but establishes a structured framework for collaboration on emerging innovations.
Under the partnership, Revival Healthcare Capital gains preferential access to MUSC's clinical expertise, research laboratories, and extensive network of clinicians and medical experts across South Carolina. This arrangement substantially reduces Revival's operational friction during early-stage due diligence by eliminating the need to source external evaluators for technology assessment. Jesse Goodwin, MUSC's chief innovation officer, emphasized that the arrangement positions MUSC as "the preferred partner for Revival when they are doing (due) diligence on technology and companies that they're looking to advance," while also facilitating streamlined clinical trials and pre-clinical testing of medical devices and health technologies.
Revival Healthcare Capital brings significant investment capacity to the partnership. In 2025, the firm co-founded Swan Endosurgical through a $458 million joint investment with Olympus Corp., a global surgery device manufacturer. Swan Endosurgical is developing an advanced robotic surgery platform targeting improved treatment of gastrointestinal tumors, underscoring Revival's focus on transformative surgical and diagnostic technologies within the medical device sector.
The partnership emerged organically from established Charleston connections. Rick Anderson, Revival's managing partner, resides in Charleston and has developed a substantive relationship with MUSC President Dr. David J. Cole in recent years, providing the foundational relationship from which the broader institutional collaboration developed. This geographic and personal alignment suggests potential for future expansion of collaborative activities between the two organizations.
Under the partnership, Revival Healthcare Capital gains preferential access to MUSC's clinical expertise, research laboratories, and extensive network of clinicians and medical experts across South Carolina. This arrangement substantially reduces Revival's operational friction during early-stage due diligence by eliminating the need to source external evaluators for technology assessment. Jesse Goodwin, MUSC's chief innovation officer, emphasized that the arrangement positions MUSC as "the preferred partner for Revival when they are doing (due) diligence on technology and companies that they're looking to advance," while also facilitating streamlined clinical trials and pre-clinical testing of medical devices and health technologies.
Revival Healthcare Capital brings significant investment capacity to the partnership. In 2025, the firm co-founded Swan Endosurgical through a $458 million joint investment with Olympus Corp., a global surgery device manufacturer. Swan Endosurgical is developing an advanced robotic surgery platform targeting improved treatment of gastrointestinal tumors, underscoring Revival's focus on transformative surgical and diagnostic technologies within the medical device sector.
The partnership emerged organically from established Charleston connections. Rick Anderson, Revival's managing partner, resides in Charleston and has developed a substantive relationship with MUSC President Dr. David J. Cole in recent years, providing the foundational relationship from which the broader institutional collaboration developed. This geographic and personal alignment suggests potential for future expansion of collaborative activities between the two organizations.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.